Be the first to like this
The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period.
The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Research’s team of industry experts. Research expects the immunoglobulin market to see a slight increase in its growth rate during the 2012–2019 forecast period. It was worth $3.6 billion in 2012, having grown at a Compound Annual Growth Rate (CAGR) of 6% from 2006.